000186515 001__ 186515
000186515 005__ 20240229145749.0
000186515 0247_ $$2doi$$a10.1038/s43018-022-00503-w
000186515 0247_ $$2pmid$$apmid:36581734
000186515 0247_ $$2altmetric$$aaltmetric:140644486
000186515 037__ $$aDKFZ-2022-03217
000186515 041__ $$aEnglish
000186515 082__ $$a610
000186515 1001_ $$00000-0002-7216-7067$$aDenkinger, Claudia M$$b0
000186515 245__ $$aAnti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
000186515 260__ $$aLondon$$bNature Research$$c2023
000186515 3367_ $$2DRIVER$$aarticle
000186515 3367_ $$2DataCite$$aOutput Types/Journal article
000186515 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698999117_23211
000186515 3367_ $$2BibTeX$$aARTICLE
000186515 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186515 3367_ $$00$$2EndNote$$aJournal Article
000186515 500__ $$a2023 Jan;4(1):96-107 / HI-TRON
000186515 520__ $$aPatients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE ) in hospitalized patients with severe COVID-19 (n = 134) within four risk groups ((1) cancer (n = 56); (2) immunosuppression (n = 16); (3) laboratory-based risk factors (n = 36); and (4) advanced age (n = 26)) randomized to standard of care (control arm) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm). No serious adverse events were observed related to the plasma treatment. Clinical improvement as the primary outcome was assessed using a seven-point ordinal scale. Secondary outcomes were time to discharge and overall survival. For the four groups combined, those receiving plasma did not improve clinically compared with those in the control arm (hazard ratio (HR) = 1.29; P = 0.205). However, patients with cancer experienced a shortened median time to improvement (HR = 2.50; P = 0.003) and superior survival with plasma treatment versus the control arm (HR = 0.28; P = 0.042). Neutralizing antibody activity increased in the plasma cohort but not in the control cohort of patients with cancer (P = 0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcomes in patients with cancer who are unable to intrinsically generate an adequate immune response.
000186515 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000186515 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186515 7001_ $$aJanssen, Maike$$b1
000186515 7001_ $$aSchäkel, Ulrike$$b2
000186515 7001_ $$aGall, Julia$$b3
000186515 7001_ $$aLeo, Albrecht$$b4
000186515 7001_ $$aStelmach, Patrick$$b5
000186515 7001_ $$aWeber, Stefan F$$b6
000186515 7001_ $$aKrisam, Johannes$$b7
000186515 7001_ $$aBaumann, Lukas$$b8
000186515 7001_ $$aStermann, Jacek$$b9
000186515 7001_ $$00000-0003-1386-3350$$aMerle, Uta$$b10
000186515 7001_ $$aWeigand, Markus A$$b11
000186515 7001_ $$aNusshag, Christian$$b12
000186515 7001_ $$aBullinger, Lars$$b13
000186515 7001_ $$aSchrezenmeier, Jens-Florian$$b14
000186515 7001_ $$aBornhäuser, Martin$$b15
000186515 7001_ $$aAlakel, Nael$$b16
000186515 7001_ $$aWitzke, Oliver$$b17
000186515 7001_ $$00000-0002-3819-9540$$aWolf, Timo$$b18
000186515 7001_ $$aVehreschild, Maria J G T$$b19
000186515 7001_ $$aSchmiedel, Stefan$$b20
000186515 7001_ $$00000-0003-2836-9224$$aAddo, Marylyn M$$b21
000186515 7001_ $$aHerth, Felix$$b22
000186515 7001_ $$aKreuter, Michael$$b23
000186515 7001_ $$aTepasse, Phil-Robin$$b24
000186515 7001_ $$aHertenstein, Bernd$$b25
000186515 7001_ $$aHänel, Mathias$$b26
000186515 7001_ $$aMorgner, Anke$$b27
000186515 7001_ $$aKiehl, Michael$$b28
000186515 7001_ $$aHopfer, Olaf$$b29
000186515 7001_ $$aWattad, Mohammad-Amen$$b30
000186515 7001_ $$aSchimanski, Carl C$$b31
000186515 7001_ $$aCelik, Cihan$$b32
000186515 7001_ $$aPohle, Thorsten$$b33
000186515 7001_ $$aRuhe, Matthias$$b34
000186515 7001_ $$aKern, Winfried V$$b35
000186515 7001_ $$aSchmitt, Anita$$b36
000186515 7001_ $$aLorenz, Hanns-Martin$$b37
000186515 7001_ $$00000-0001-6923-0590$$aSouto-Carneiro, Margarida$$b38
000186515 7001_ $$aGaeddert, Mary$$b39
000186515 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b40$$udkfz
000186515 7001_ $$aMeuer, Stefan$$b41
000186515 7001_ $$aKräusslich, Hans-Georg$$b42
000186515 7001_ $$aMüller, Barbara$$b43
000186515 7001_ $$aSchnitzler, Paul$$b44
000186515 7001_ $$aParthé, Sylvia$$b45
000186515 7001_ $$aBartenschlager, Ralf$$b46
000186515 7001_ $$aGronkowski, Martina$$b47
000186515 7001_ $$aKlemmer, Jennifer$$b48
000186515 7001_ $$aSchmitt, Michael$$b49
000186515 7001_ $$aDreger, Peter$$b50
000186515 7001_ $$aKriegsmann, Katharina$$b51
000186515 7001_ $$aSchlenk, Richard F$$b52
000186515 7001_ $$aMüller-Tidow, Carsten$$b53
000186515 773__ $$0PERI:(DE-600)3005299-3$$a10.1038/s43018-022-00503-w$$n1$$p96-107$$tNature cancer$$v4$$x2662-1347$$y2023
000186515 909CO $$ooai:inrepo02.dkfz.de:186515$$pVDB
000186515 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b40$$kDKFZ
000186515 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000186515 9141_ $$y2022
000186515 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2022-11-08$$wger
000186515 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-08
000186515 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000186515 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000186515 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT CANCER : 2022$$d2023-08-26
000186515 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000186515 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000186515 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000186515 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-26
000186515 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000186515 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000186515 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bNAT CANCER : 2022$$d2023-08-26
000186515 9201_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x0
000186515 980__ $$ajournal
000186515 980__ $$aVDB
000186515 980__ $$aI:(DE-He78)D240-20160331
000186515 980__ $$aUNRESTRICTED